TESARO (TSRO) Misses Q1 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
TESARO Announces First-Quarter 2017 Operating Results
May 9, 2017 4:06 PM EDTZEJULA approved by U.S. FDA for the maintenance treatment of women with recurrent ovarian cancer, regardless of BRCA or biomarker status; commercial launch underwayZEJULA added to the NCCN Clinical Practice Guidelines in Oncology Expanded development program for niraparib in ovarian, lung and breast cancers to begin 2H 2017VARUBY® approved in Europe and launches to begin late 2Q 2017VARUBI® IV NDA re-submitted to FDA; approval anticipated late 2Q 2017 TSR-042 clinical program now open to enroll patients with MSI-H endometrial... More
